• IceCure Medical added Adventist Health Glendale as the first U.S. site enrolling patients in its post-marketing ChoICE study of ProSense for low-risk breast cancer.
• No study results were presented; the trial will collect real-world evidence to support broader clinical adoption and patient access.
• The study targets up to 400 patients across multiple U.S. sites, extending data generation following FDA marketing authorization in October 2025.
• Adventist Health Glendale will be led by breast surgeon Dennis Holmes, a researcher in breast cancer cryoablation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.